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Running title: In vitro susceptibility of Fusarium. 24 
 25 
Abstract 26 
Background 27 
Fungal keratitis is a common but severe eye infection in tropical and subtropical areas of the 28 
world. In regions with a temperate climate the frequency is rising in patients with contact 29 
lenses and following trauma. Early and adequate therapy is important to prevent disease 30 
progression and loss of vision. The management of Fusarium keratitis is complex, and the 31 
optimal treatment is not well defined. We investigated the in vitro activity of chlorhexidine 32 
and seven antifungal agents against a well characterized collection of Fusarium isolates, 33 
recovered from patients with Fusarium keratitis. 34 
Patients and methods 35 
The fungus culture collection of the Center of Expertise in Mycology Radboudumc/CWZ was 36 
searched for Fusarium isolates that were cultured from cornea scrapings, ocular biopsies, eye 37 
swabs and contact lens fluid containers from patients suspected of keratitis. The Fusarium 38 
isolates that were cultured from patients with confirmed keratitis were all identified using 39 
conventional and molecular techniques. Antifungal susceptibility testing was performed 40 
according to the EUCAST broth microdilution reference method. The antifungal agents tested 41 
included amphotericin B, voriconazole, posaconazole, miconazole, natamycin, 5-42 
fluorocystosine, and caspofungin. In addition, the activity of chlorhexidine was determined. 43 
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Results 44 
The fungal culture collection contained 98 Fusarium isolates of confirmed fungal keratitis 45 
cases from 83 Dutch patients and 15 Tanzanian patients. The isolates were collected between 46 
2007 and 2017. F. oxysporum (n=24, 24.5%) was the most frequently isolated species 47 
followed by F. solani sensu stricto (n=18, 18.4%) and F. petroliphilum (n=11, 11.2%). In 48 
vitro amphotericin B was the most active antifungal drug followed by natamycin, 49 
voriconazole, posaconazole, and miconazole. Chlorhexidine showed activity against all. 5-50 
Fluorocytosine showed no in vitro activity. 51 
Conclusion 52 
Amphotericin B showed the most favorable in vitro inhibition of Fusarium species followed 53 
by natamycin, voriconazole and chlorhexidine, while 5-fluorocytosine, posaconazole, 54 
miconazole and caspofungin showed no relevant inhibiting effect. However, chlorhexidine 55 
showed fungicidal activity against 90% of F. oxysporum strains and 100% of the F. solani 56 
strains. 57 
Our study supports the clinical efficacy of chlorhexidine, and therefore warrants its further 58 
clinical evaluation for primary therapy of fungal keratitis, particularly in low and middle 59 
income countries where fungal keratitis is much more frequent and currently antifungal eye 60 
drops are often unavailable.  61 
 62 
Introduction  63 
Fungal keratitis is a common eye infection in tropical and subtropical areas of the world. In 64 
regions with a temperate climate fungal keratitis is uncommon, but mainly reported in patients 65 
with contact lenses and following trauma. Early therapy is important to prevent disease 66 
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progression or dissemination. A major complication of fungal keratitis is monocular 67 
blindness, especially in tropical low and middle income countries (LMIC), where significant 68 
delay in diagnosis and simply the unavailability of antifungals are common. Most cases of 69 
fungal keratitis are caused by Fusarium species,
1,2
 which are ubiquitous fast-growing 70 
hyalohyphomycetes that are present in soil, water, and plants. The most common route of 71 
infection is by (micro)trauma or disruptive ocular surface disease, as filamentous fungi are 72 
unable to penetrate intact cornea.  73 
The taxonomy of the Fusarium order is complex and still not well defined. Molecular 74 
techniques have shown that the common medically relevant species, F. solani and F. 75 
oxysporum, consist of multiple (sub)species.
3
 Although, in vitro antifungal susceptibility 76 
patterns of Fusarium species may vary greatly within each species, most species show high 77 
minimal inhibitory concentrations (MICs) to the currently licensed antifungals.
4-7
. The 78 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) has not defined 79 
epidemiological cut-off (ECOFF) values and clinical breakpoints for Fusarium species. In 80 
2015 Espinel-Ingroff et al. published epidemiological cut-off values (ECVs) based on the 81 
Clinical & Laboratory Standards Institute (CLSI) broth dilution method for antifungal 82 
susceptibility testing (AFST).
8
 As topical antifungal therapy is important for fungal keratitis 83 
management, meaningful classification of isolates as resistant or susceptible is a challenge. 84 
These factors complicate the management of Fusarium keratitis,
9
 and the optimal treatment is 85 
not well defined.  86 
Currently, a 0.02% chlorhexidine solution is used for the treatment of Acanthamoeba 87 
keratitis. A few studies have indicated that the disinfectant chlorhexidine might be an 88 
effective, affordable and accessible treatment for fungal keratitis, which could benefit millions 89 
of people who currently have no options.
10, 11
 The meta-analysis in the Cochrane systematic 90 
review written by FlorCruz and Evans show that chlorhexidine has a better clinical outcome 91 
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than natamycin and voriconazole.
12
 To our knowledge, there are no published data describing 92 
the MICs of chlorhexidine for Fusarium species. In this study, we investigated the in vitro 93 
activity of chlorhexidine and seven antifungal agents against a molecularly characterized set 94 
of Fusarium isolates, recovered from patients with keratitis.  95 
 96 
Results 97 
The fungal culture collection contained 98 Fusarium isolates from 83 patients with keratitis 98 
from the Netherlands and 15 with keratitis from Tanzania. The isolates were collected 99 
between 2007 and 2017. The first Fusarium isolate per patient was tested.  100 
Molecular identification showed that F. oxysporum (n=24, 24.5%) was the most frequently 101 
isolated species followed by F. solani sensu stricto (n=18, 18.4%) and F. petroliphilum 102 
(n=11, 11.2%). Based on the assignment of the isolates to the according species complex, as 103 
described by Salah et al.
3
, the most frequently encountered complexes were F. solani species 104 
complex (FSSC, n=43, 43.9%), F. oxysporum species complex (FOSC, n=24, 24.5%), F. 105 
fujikuroi species complex (FFSC, n=16, 16.3%) and F. dimerum species complex (FDSC, 106 
n=12, 12.2%). One isolate could not be assigned to any species complex or species and seems 107 
to be a new Fusarium species.  108 
The MIC distribution for the various species and species complexes are shown in Tables 1 109 
and 2. In vitro amphotericin B was the most active antifungal drug followed by natamycin, 110 
voriconazole, posaconazole, and miconazole. Chlorhexidine showed activity against all 111 
species at a concentration of 8 to 32 mg/l, which corresponds with 1.56x10
-3
 to 6.25x10
-3
%. 112 
5-Fluorocytosine showed no in vitro activity.  113 
Statistics. The median MIC and the MIC distributions of 5-fluorocytosine and caspofungin 114 
showed no differences between any of the groups.  115 
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The MIC distributions of amphotericin B showed significant difference between the species 116 
complexes (Kruskal Wallis test, p = 0.002). The FDSC differed significant from FSSC and 117 
from FFSC. 118 
For voriconazole the median MIC and the MIC distributions showed significant difference 119 
between the species complexes (p = 0.006 resp. p = 0.000, Kruskal Wallis test). The FSSC 120 
differed significant from FOSC, from FFSC and from FDSC.  121 
The MIC distributions of posaconazole and miconazole showed significant difference 122 
between the species complexes (p = 0.000 resp. p = 0.001, Kruskal Wallis test). For 123 
posaconazole and miconazole the FFSC differed significant from FSSC and from FOSC.  124 
The median MIC of natamycin was not different between the SC groups (p = 0.747, Kruskal-125 
Wallis). On the other hand the MIC distributions of natamycin differed significant between 126 
the species complexes (p=0.015, Kruskal Wallis test). The FDSC differed significant from 127 
FSSC, from FOSC and from FFSC.  128 
The median MIC and the MIC distributions of chlorhexidine showed significant difference 129 
between the species complexes (p = 0.000 resp. p = 0.000, Kruskal Wallis test). The FSSC 130 
differed significant from FOSC, from FFSC and from FDSC. 131 
MIC values of posaconazole, miconazole, 5-fluorocytosine and caspofungin were high so 132 
determining the MFC of these agents was deemed clinically not relevant.  133 
In vitro amphotericin B exhibited fungicidal effect on 60% of the F. oxysporum strains and 134 
70% of the F. solani strains, the remainder of the strains showed a fungistatic effect (see 135 
figure 1). Natamycin was fungicidal against 80% of the F. oxysporum strains. However, in F. 136 
solani strains natamycin was mostly fungistatic, in only 30% it acted fungicidal. Voriconazole 137 
was fungicidal against 30% of the F. oxysporum strains and 50% of the F. solani strains. 138 
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Chlorhexidine showed fungicidal activity against 90% of F. oxysporum strains and 100% of 139 
the F. solani strains. 140 
 141 
Discussion and conclusions 142 
Chlorhexidine showed broad in vitro activity against all Fusarium species tested and 143 
compared with the antifungal agents showed the broadest fungicidal activity against the two 144 
species tested. Although it is likely that chlorhexidine is fungicidal in other Fusarium species, 145 
this was not tested. For chlorhexidine 95% of the 20 Fusarium isolates were killed at 146 
concentrations far below the 0.02% and 0.2% concentration, of which the 0.02% eye drops is 147 
already commonly used by ophthalmologists for treatment of Acanthamoeba keratitis. 148 
Another important advantage of chlorhexidine gluconate solution is the broad antimicrobial 149 
spectrum including Gram-positive and Gram-negative bacteria, lipid-enveloped viruses and 150 
Acanthamoeba.
12, 16
  151 
A limited number of clinical trials have studied the effectiveness of chlorhexidine gluconate 152 
for the treatment of fungal keratitis. The aim of one trial was to find the most effective dose of 153 
chlorhexidine.
17
 In comparison to the response with natamycin, the relative efficacy in a 154 
patient without prior antifungal treatment was 1.17 with chlorhexidine 0.05%, 1.43 with 155 
chlorhexidine 0.1% and 2.00 with chlorhexidine 0.2%. Their fungal isolates were not 156 
subjected to molecular identification and susceptibility testing. The second study of Rahman 157 
et al. showed a relative efficacy of 1.85 (CI 1.01-3.39, p = 0.04) with chlorhexidine 0.2% in 158 
comparison to natamycin. Of the non-severe ulcers 66.7% was healed at day 21 with 159 
chlorhexidine and 36.0% with natamycin. However, this trial was not double blinded due to 160 
the fact that personnel could identify the selected treatment because the solutions of 161 
chlorhexidine and natamycin were visibly different.
10
 The susceptibility testing was 162 
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performed with a non-reference well diffusion method (0.2% chlorhexidine, 2.5% natamycin, 163 
1% econazole). The concentration of natamycin used was 2.5%, which is half the current 164 
standard therapeutic concentration of 5%. In addition, the method of identification of the 165 
strains was also not mentioned. 166 
In the Netherlands, the available antifungal agents, which can be used as eye drops are 167 
amphotericin B 0.15% (1,500 mg/L), voriconazole 1% (10.000 mg/L) and the disinfectant 168 
chlorhexidine 0.02% (200 mg/L). These formulas are not commercially available but are 169 
prepared by hospital pharmacists on request. In other countries natamycin (5% suspension; 170 
50.000 mg/L) is available and frequently used in the setting of fungal keratitis.
2, 10-12, 18-23
 171 
These concentrations exceed by far the in vitro determined MICs of the Fusarium isolates 172 
(tables 1 and 2). However, effectiveness depends on many factors including the ability of the 173 
compound to penetrate ocular tissues, local bioavailability, and drug toxicity.  174 
The most important route of penetration of topical antifungals into ocular tissue is through the 175 
cornea, mostly by diffusion. The polyenes, amphotericin B and natamycin, are compounds 176 
with a high molecular mass (i.e. > 500 Da) and as a consequence barely penetrate intact 177 
cornea epithelium.
24
 This leads to the necessity of regularly performing abrasions of the 178 
cornea during treatment with amphotericin B. In high doses, amphotericin B can be toxic to 179 
the cornea but the 0.15% solution is well tolerated.
24
 Due to the viscous nature of natamycin 180 
suspension and its poor penetration it is only suitable for treatment of superficially located 181 
keratomycosis. Furthermore, compounds that are lipophilic can penetrate across the corneal 182 
stroma, while hydrophilic agents are able to penetrate all the layers of the cornea. 183 
There is little known about the corneal penetration of the cationic antisepticum chlorhexidine 184 
gluconate. In a small animal study Vontobel et al. showed that the compound did not 185 
penetrate through the intact or mechanically damaged cornea into the anterior chamber.
25
 It 186 
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seems that chlorhexidine accumulates within the cornea, explaining the need to treat deep 187 
seeted Acanthamoeba for a long time. 188 
Amphotericin B showed the most favorable in vitro inhibition of Fusarium species followed 189 
by natamycin, voriconazole and chlorhexidine, while 5-fluorocytosine, posaconazole, 190 
miconazole and caspofungin showed no relevant inhibiting effect. However, chlorhexidine 191 
showed fungicidal activity against 90% of F. oxysporum strains and 100% of the F. solani 192 
strains.  193 
The differences in AFST between isolates belonging to the same species complex justifies 194 
conducting molecular identification to species complex level. In general, the species 195 
belonging to the FDSC and the FFSC are more susceptible to chlorhexidine, amphotericin B, 196 
natamycin, voriconazole and posaconazole (only FFSC). These differences cannot be 197 
predicted by identification based on conventional methods because the characteristics of 198 
morphology and microscopy are not species specific.  199 
Our study supports the clinical efficacy of chlorhexidine, and therefore warrants its further 200 
clinical evaluation for primary therapy of fungal keratitis, particularly in LMIC where fungal 201 
keratitis is much more frequent and currently antifungal eye drops are often unavailable. 202 
Further studies should investigate the in vitro interaction of chlorhexidine with antifungal 203 
agents to support alternate administration and combination therapy. 204 
 205 
Patients and methods 206 
The fungus culture collection of the Center of Expertise in Mycology Radboudumc/CWZ was 207 
searched for Fusarium isolates that were cultured from cornea scrapings, ocular biopsies, eye 208 
swabs and contact lens fluid containers from patients suspected of keratitis. All isolates had 209 
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been identified up to genus level using conventional techniques. For accurate species 210 
identification, sequencing of the TEF1 gene was performed.
3
 211 
Antifungal susceptibility testing was performed according to the EUCAST broth 212 
microdilution reference method.
13, 14
 The antifungal agents tested included amphotericin B 213 
(Bristol Myers Squibb), voriconazole (Pfizer), posaconazole (Merck & Co), miconazole 214 
(Janssen Cilag), natamycin (Sigma-Aldrich), 5-fluorocystosine (Hoffman la Roche), and 215 
caspofungin (Merck & Co). In addition, the activity of chlorhexidine (Pharmaline) was 216 
determined. The test range of the antifungal agents was 0.02 – 16 mg/L for amphotericin B, 217 
voriconazole, posaconazole, miconazole, caspofungin and natamycin, and 0.03 – 32 mg/L for 218 
5-fluorocytosine. For chlorhexidine a concentration range of
 
1 to 1024 mg/L was used which 219 
corresponds with 0.000195% to 0.2%. All antifungal agents and chlorhexidine were dissolved 220 
in RPMI 1640 supplemented with glucose to a final concentration of 2%. The MICs were 221 
determined with an inverted mirror after 48 hours at 35°C as the lowest drug concentration 222 
with complete inhibition of growth visible by eye for amphotericin B, voriconazole, 223 
posaconazole, miconazole, natamycin, 5-fluorocystosine and chlorhexidine. The endpoint for 224 
echinocandins was the minimal effective concentration (MEC). The MEC for caspofungin 225 
was determined with an inverted microscope after 48 hours at 35°C as the lowest drug 226 
concentration in which abnormal, short, and branched hyphal clusters are observed in contrast 227 
to the long, unbranched, elegant hyphal elements that are visible in the growth control well. 228 
Aspergillus fumigatus ATCC 204305 and Aspergillus flavus ATCC 204304 were used as 229 
quality control strains as recommended by the EUCAST.
13
 230 
Ten F. oxysporum and 10 F. solani were used to determine the minimal fungicidal 231 
concentration (MFC) for the antifungal agents and chlorhexidine. After reading the MICs at 232 
48 h, the 96-wells plates were shaken to loosen the fungal elements. Thereafter, 20l of all the 233 
wells with no visible growth and 20l of the growth control were plated on Sabouraud agar 234 
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(Oxoid). The plates were incubated for 24 and 48 hours at 35°C. The MFC was determined as 235 
the lowest drug concentration, which leads to 99-99.5% growth inhibition compared to the 236 
growth control. Antifungal agents were considered fungicidal when the MIC value was no 237 
more than two dilution steps lower than the MFC.
15
 If the difference between MIC and MFC 238 
was > 2 dilution steps the antifungal agent was classified as fungistatic.
15
  239 
Statistical analysis was performed with IBM SPSS Statistics 24. In vitro susceptibility 240 
differences between Fusarium species and differences between species complexes were tested 241 
with a non-parametric test (one-way ANOVA, Kruskal-Wallis). A p-value of <0.05 was 242 
determined as significant. In order to correct for multi-testing in the search for which group(s) 243 
differed from each other the p-value was adjusted according to the Bonferroni correction 244 
method (e.g. significance level [<0.05] divided by the number of tests needed). The 245 
Bonferonni correction for the species groups was p < 0.0011, for the species complex groups 246 
the Bonferonni was p < 0.0083. Species and species complexes with only one isolate where 247 
not taken into account in the statistical analysis. For every antifungal or antiseptic agent we 248 
tested for significant differences between the species complexes by comparing the median 249 
MIC or percentage of the concentration and comparing the distributions between the groups. 250 
After this comparison the groups which were responsible for the significant difference were 251 
determined through comparing one group to another group with the Mann-Whitney U test. 252 
The collection of samples from Dutch participants were collected during the routine standard 253 
of care. Therefore, we didn’t need their informed consent in accordance to the Dutch Ethics 254 
Committee of the Radboud University Medical Center. 255 
The collection of samples from Tanzanian participants was approved by the Ethics 256 
Committees of the National Institute for Medical Research, Tanzania and the London School 257 
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of Hygiene & Tropical Medicine, United Kingdom.  Informed consent was obtained from all 258 
participants.  259 
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Figure 1. The proportion of fungicidal and fungistatic in vitro effect of amphotericin B, natamycin, voriconazole and the disinfectant 278 
chlorhexidine depicted of Fusarium oxysporum (n=10) and Fusarium solani (n=10), all of which were isolated from patients with fungal 279 
keratitis. Blue is fungicidal (upper proportion of the bars) and green is fungistatic proportion. 280 
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Table 1. Molecularly identified fusarial keratitis isolates and their susceptibility profile to eight antifungal agents including chlorhexidin and natamycin. 
 
MIC* % [median (range)] MIC* mg/L [median (range)] MEC* mg/L [median (range)] 
Fusarium species (n) CHX CHX AMB VCZ 5-FC MCZ NAT POS CAS 
F. species (1) 0.003 16 0.5 2 32 16 8 16 16 
F. falciforme (7) 0.006 (0.002-0.006) 32 (8-32) 2 (1-8) 16 (8-16) >32 (>32) 16 (16) 8 (8-16) 16 (16) 16 (16) 
F. keratinoplasticum (7) 0.003 (0.002-0.006) 16 (8-32) 4 (2-4) 8 (4-16) >32 (>32) 16 (16) 4 (4-8) 16 (16) 16 (0.5-16) 
F. petroliphilum (11) 0.003 (0.002-0.006) 16 (8-32) 2 (0.5-4) 8 (4-16) >32 (>32) 16 (16) 4 (4-8) 16 (16) 16 (2-16) 
F. solani (18) 0.006 (0.002-0.006) 32 (8-32) 2 (0.063-16) 8 (4-16) >32 (>32) 16 (8-16) 8 (4-16) 16 (8-16) 16 (4-32) 
F. oxysporum (24) 0.002 (0.0002-0.012) 8 (1-64) 2 (0,25-16) 4 (2-16) 32 (0.063-32) 16 (16) 8 (4-8) 16 (16) 16 (0.063-32) 
F. musae (1) 0.003 16 2 4 >32 8 8 1 16 
F. verticillioides (3) 0.003 (0.001-0.003) 16 (4-16) 2 (1-8) 2 (1-2) >32 (>32) 1 (0.25-8) 8 (2-8) 0.5 (0.25-1) 16 (16) 
F. proliferatum (7) 0.002 (0.001-0.012) 8 (4-64) 2 (1-4) 4 (2-8) >32 (>32) 16 (16) 8 (4-8) 4 (2-16) 16 (16) 
F. ramigenum (1) 0.003 16 4 1 >32 16 4 1 16 
F. sacchari (1) 0.002 8 2 1 >32 4 8 0.25 16 
F. lactis (3) 0.002 (0.002-0.003) 8 (8-16) 2 (0.5-4) 4 (2-8) >32 (>32) 16 (16) 8 (8) 16 (2-16) 16 (16) 
F. equiseti (1) † † 1 8 † † † 16 32 
F. dimerum (8) 0.002 (0.002-0.003) 8 (8-16) 1 (0.5-2) 8 (4-8) >32 (>32) 16 (16) 4 (4-16) 16 (16) 16 (2-16) 
F. delphinoides (4) 0.001 (0.001-0.002) 4 (4-8) 0.5 (0.125-1) 2 (2) >32 (>32) 16 (16) 4 (2-4) 8 (1-16) 16 (2-16) 
F. ambrosium (1) 0.006 32 2 16 >32 16 8 16 1 
*MIC, minimal inhibitory concentration; MEC, minimal effective concentration. 
*AMB, amphotericin B; VCZ, voriconazole; POS, posaconazole; MCZ, miconazole; NAT, natamycin; 5FC, 5-fluorocytosin; CHLX, chlorhexidine; CAS, caspofungin. 
†susĐeptiďility testiŶg for this aŶtifuŶgal ageŶt was Ŷot perforŵed. 
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Table 2. Fusarial keratitis isolates assigned according to the species complex and their susceptibility profile to eight antifungal agents including chlorhexidin and natamycin. 
 
MIC* %  
[median (range)] MIC* mg/L [median (range)] 
MEC* mg/L  
[median (range)] 
Fusarium species complex (n) CHX CHX AMB VCZ 5-FC MCZ NAT POS CAS 
Unknown (1) 0.003 16 0.5 2 32 16 8 16 16 
F. solani species complex - FSSC (43) 0.003 (0.002-0.006)
δ
 16 (8-32) 2 (0.063-16) 8 (4-16)
δ
 >32 (>32) 16 (8-16) 8 (4-16) 16 (8-16) 16 (0.5-32) 
F. oxysporum species complex - FOSC (24) 0.002 (0.002-0.012) 8 (2-64) 2 (0.25-16) 4 (2-16) 32 (0.063-32) 16 (16) 8 (4-8) 16 (16) 16 (0.063-32) 
F. fujikuroi species complex - FFSC (16) 0.002 (0.001-0.012) 8 (4-64) 2 (0.5-8) 4 (1-8) >32 (>32) 16 (0.25-16)
δ
 8 (2-8) 2 (0.25-16)
δ
 16 (16) 
F. incarnatus-equiseti species complex - FIESC (1) † † 1 8 † † † 16 32 
F. dimerum species complex - FDSC (12) 0.002 (0.0008-0.003) 8 (4-16) 1 (0.125-2)
δ
 8 (2-8) >32 (>32) 16 (16) 4 (2-16)
δ
 16 (1-16) 16 (2-16) 
Ambrosia Fusarium Clade - AFC (1) 0.006 32 2 16 >32 16 8 16 1 
*MIC, minimal inhibitory concentration; MEC, minimal effective concentration. 
*AMB, amphotericin B; VCZ, voriconazole; POS, posaconazole; MCZ, miconazole; NAT, natamycin; 5FC, 5-fluorocytosin; CHLX, chlorhexidine; CAS, caspofungin. 
†susĐeptiďility testiŶg for this aŶtifuŶgal ageŶt was Ŷot perforŵed. 
δSignificant difference of the median and or distribution range between the groups of species complex. 
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